## MDT: Medtronic plc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -3.8% below STRENGTH zone (4.0-10.0%); PEG 3.73 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($94.41)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Medtronicâ€™s diabetes spinoff MiniMed files for IPO**
- Source: MedTech Dive | 20251222T160446 | Somewhat-Bearish | Relevance: 100%
- Medtronic's diabetes spinoff, MiniMed, has filed for an initial public offering, despite reporting a $198 million loss on sales of $2.72 billion in its 2025 fiscal year. The company aims to leverage its broad portfolio of insulin pumps and glucose sensors to generate more revenue per customer, positioning itself against more specialized competitors. However, MiniMed faces challenges with the profitable manufacturing and scaling of its Simplera CGM sensor, which has led to significant charges and a decline in U.S. insulin pump sales.

**2. Medtronic announces cash dividend for second quarter of fiscal year 2025**
- Source: GuruFocus | 20251220T160824 | Bullish | Relevance: 100%
- Medtronic plc declared a cash dividend of $0.70 per ordinary share for the second quarter of fiscal year 2025, consistent with its earlier announcement in May 2024. The dividend is payable on October 11, 2024, to shareholders of record as of September 27, 2024. Medtronic is noted as an S&P 500 Dividend Aristocrat, having increased its annual dividend for 47 consecutive years.

**3. Voya Investment Management LLC Sells 65,841 Shares of Medtronic PLC $MDT**
- Source: MarketBeat | 20251220T140828 | Somewhat-Bullish | Relevance: 100%
- Voya Investment Management LLC reduced its stake in Medtronic PLC by 8.8% in Q3 2025, selling 65,841 shares. Despite this, Medtronic reported strong Q3 earnings, beating expectations, and announced a quarterly dividend. The company is also pursuing an IPO for its Diabetes unit, MiniMed, as a planned separation.

**4. Perkins Coie Trust Co Decreases Holdings in Medtronic PLC $MDT**
- Source: MarketBeat | 20251220T120807 | Somewhat-Bullish | Relevance: 100%
- Perkins Coie Trust Co significantly reduced its stake in Medtronic PLC (NYSE:MDT) by 96.5% during Q3, selling over a million shares. The medical technology company, Medtronic, meanwhile, is pursuing an IPO for its Diabetes unit, MiniMed, intending to retain majority control, and has reported strong quarterly earnings and future EPS guidance. Analysts generally rate Medtronic as a "Moderate Buy" with a consensus target price of $109.94.

**5. Medtronic's Diabetes Unit MiniMed Files For US IPO**
- Source: Benzinga | 20251220T022904 | Somewhat-Bullish | Relevance: 100%
- Medtronic's (NYSE: MDT) diabetes unit, MiniMed Group, has filed for a U.S. initial public offering (IPO) as part of its separation from the parent company. MiniMed reported a net loss of $21 million on sales of $1.48 billion in the six months ending October 24. Medtronic plans to retain at least 80.1% of MiniMed's voting stock post-IPO and will list the company on Nasdaq under the symbol "MMED."

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Truist Securiti | $107 | $110 | -3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Truist Securiti | main | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 6 ($0.53M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+0.1%)
- Blackrock Inc.: 9.3% (-2.4%)
- JPMORGAN CHASE & CO: 8.1% (+197.7%)
- State Street Corpora: 4.7% (+1.1%)
- Capital Research Glo: 2.4% (-15.6%)

### Key Risks

1. Valuation stretched: PEG 3.7x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.73 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (2.4x). Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $125.3B |
| Beta | 0.72 |
| 52W Range | $79.29 - $106.33 |
| Short Interest | 1.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.73 |
| Forward P/E | 16.0 |
| Current P/E | 17.3 |
| YoY Growth | 8.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at -3.8% (minimal 5-day change). Below STRENGTH zone by 7.8pp (needs >4.0% for momentum thesis). AM_20 at -3.3% indicates price below own 20MA trend. Underperforming sector by 3.7pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.07x) but short-term weakness (below SMA20). MACD histogram bearish (-0.63), momentum weakening. RSI neutral at 44. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.84% (CS: 14) | Weak |
| RSI_14 | 43.5 | Neutral |
| MACD Histogram | -0.63 | Bearish |
| vs SMA20 | 0.967x | Below |
| vs SMA50 | 1.005x | Above |
| vs SMA200 | 1.072x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $97.71
- **Stop Loss:** $94.41 (3.4% risk)
- **Target:** $101.01 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 363
- **Position Value:** $35,468.73
- **Portfolio %:** 35.47%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-17 (Est: $1.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.31 | $1.36 | +3.5% |
| 2025Q3 | $1.23 | $1.26 | +2.5% |
| 2025Q2 | $1.58 | $1.62 | +2.7% |
| 2025Q1 | $1.36 | $1.39 | +2.2% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*